In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Halozyme Therapeutics Inc (NASDAQ: HALO) closed at $58.21 up 1.61% from its previous closing price of $57.29. In other words, the price has increased by $1.61 from its previous closing price. On the day, 1.43 million shares were traded. HALO stock price reached its highest trading level at $58.44 during the session, while it also had its lowest trading level at $57.4.
Ratios:
For a deeper understanding of Halozyme Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.35. For the most recent quarter (mrq), Quick Ratio is recorded 6.78 and its Current Ratio is at 7.80. In the meantime, Its Debt-to-Equity ratio is 4.22 whereas as Long-Term Debt/Eq ratio is at 4.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on October 07, 2024, Downgraded its rating to Equal Weight and sets its target price to $62 from $58 previously.
On September 19, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also upped its target price recommendation from $52 to $57.
Piper Sandler Downgraded its Overweight to Neutral on June 07, 2024, whereas the target price for the stock was revised from $48 to $51.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 01 ’25 when Henderson Jeffrey William sold 503 shares for $64.05 per share. The transaction valued at 32,217 led to the insider holds 33,108 shares of the business.
Henderson Jeffrey William sold 5,000 shares of HALO for $293,458 on Mar 03 ’25. The Director now owns 33,611 shares after completing the transaction at $58.69 per share. On Feb 26 ’25, another insider, LaBarre Michael J., who serves as the SVP, CHIEF TECHNICAL OFFICER of the company, sold 10,000 shares for $58.12 each. As a result, the insider received 581,244 and left with 175,453 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 7262512128 and an Enterprise Value of 8109165056. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.96, and their Forward P/E ratio for the next fiscal year is 8.34. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.08 while its Price-to-Book (P/B) ratio in mrq is 19.70. Its current Enterprise Value per Revenue stands at 7.987 whereas that against EBITDA is 12.931.
Stock Price History:
The Beta on a monthly basis for HALO is 1.26, which has changed by 0.48798573 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $66.00, while it has fallen to a 52-week low of $37.97. The 50-Day Moving Average of the stock is -3.55%, while the 200-Day Moving Average is calculated to be 4.14%.
Shares Statistics:
For the past three months, HALO has traded an average of 1.43M shares per day and 1674450 over the past ten days. A total of 123.14M shares are outstanding, with a floating share count of 122.22M. Insiders hold about 1.06% of the company’s shares, while institutions hold 100.23% stake in the company. Shares short for HALO as of 1743379200 were 9221727 with a Short Ratio of 6.46, compared to 1740700800 on 9748013. Therefore, it implies a Short% of Shares Outstanding of 9221727 and a Short% of Float of 10.209999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
